Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CETRA: Neoadjuvant Trastuzumab and Chemotherapy in HER2+ Breast Cancer
NCT00434031Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Sep 2007
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Targeted Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pegylated liposomal doxorubicin in HER2-positive breast cancer, sponsored by National Cancer Institute. Primary endpoint: complete pathologic response rate. Planned start Sep 2007; status: withdrawn.
02
Drugs
trastuzumabpegylated liposomal doxorubicin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00434031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00434031.